Trials / Completed
CompletedNCT01896323
CC-223 and Ketoconazole Drug-Drug Interaction Study
An Open-Label, Two-Period, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Single Dose Pharmacokinetics of CC-223 in Healthy Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Celgene · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center open-label study to compare how CC-223 (the study drug being investigated) interacts with the drug ketoconazole.
Detailed description
This is a 2 period study, which lasts about 6 weeks long. About 14 males will be entered into the study, during which they will receive the study drug (a single dose of 20 mg CC-223) 400 mg ketoconazole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-223 | CC-223 20 mg tablets |
| DRUG | Ketoconazole | Ketoconazole 400 mg tablets |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2013-07-11
- Last updated
- 2019-11-12
Source: ClinicalTrials.gov record NCT01896323. Inclusion in this directory is not an endorsement.